Potential therapeutic targets for schizophrenia

Bibliography

• KAPLAN HI, SADDOCK BJ, GREBB JA: In: Comprehensive Textbook of Psychiatry (Edition 7). Williams and Wilkins, Baltimore, Maryland, USA (1994).
   Google Scholar
• JABLENSKY A: Multicultural studies and the nature of schizophrenia: a review. J. Roy. Soc. Med. (1987) 80(3):162–167.
   PubMed Web of Science ®Google Scholar
• SARTORIUS N, JABLENSKY A, KORTEN A: Early manifes-tations and first contact incidence of schizophrenia in different cultures: a preliminary report on the initial evaluation phase of the WHO collaborative study on determinants of outcome of severe mental disorders. Psycho]. Med. (1986) 16(4):909–928.
   PubMedGoogle Scholar
• BEISER M, IACONO WG: An update on the epidemiology of schizophrenia. Can. J. Psychiatry (1990) 35 (8):657–668.
   PubMedGoogle Scholar
• WONG AH, VORUGANTI LN, HESLEGRAVE RJ, AWAD AG: Neurocognitive deficits and neurological signs in schizophrenia. Schizophr. Res. (1997) 23 (2):139–146.
   PubMedGoogle Scholar
• CARPENTER WT, BUCHANAN RW: Schizophrenia. New Eng. J. Med. (1994) 10(330):681–90.
   Google Scholar
• DSM-IV: In: Diagnostic and Statistical Manual of Mental Disorders (Edition 4). American Psychiatric Association, Washington DC, USA (1994).
   Google Scholar
• WORLD HEALTH ORGANISATION: The ICD-10 classifica-tion of mental and behavioural disorders: clinical descriptions and diagnostic guidelines: 10th revision. World Health Organisation, Geneva (1992).
   Google Scholar
• STEFANIS CN: Schizophrenia: neurobiological perspec-tives. Progress in Brain Research (1994) 100:267–272.
   PubMedGoogle Scholar
• KAHN RS, DAVIS KL: New developments in dopamine and schizophrenia. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ (Eds.), Raven Press Ltd., New York, USA (1995).
   Google Scholar
• SCHULTZ SK, ANDREASEN NC: Schizophrenia. Lancet (1999) 353(9162):1425–1430.
   PubMed Web of Science ®Google Scholar
• •A good, recent review of schizophrenia.
   Google Scholar
• LARUELLE M, ABI-DARGHAM A, VAN DYCK CH et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. ScL USA (1996) 93 (17) 9235–9240
   PubMed Web of Science ®Google Scholar
• LARUELLE M: Imaging dopamine transmission in schizophrenia: a review and meta- analysis. Q J Nucl. Med. (1998) 42(3):211–221.
   PubMedGoogle Scholar
• GINOVART N, FARDE L, HALLDIN C, SWAHN CG: Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates [In Process Citation]. Synapse (1999) 31 (2) :154–162.
   PubMedGoogle Scholar
• BREIER A, SU TP, SAUNDERS R et al.: Schizophrenia isassociated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA (1997) 94(6):2569–2574.
   PubMed Web of Science ®Google Scholar
• ABI-DARGHAM A, GIL R, KRYSTAL J et al.: Increasedstriatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry (1998) 155(6):761–767.
   PubMed Web of Science ®Google Scholar
• CANNON TD, VAN ERP TG, HUTTUNEN M et.al.: Regional gray matter, white matter, and cerebrospinal fluid distributions in schizophrenic patients, their siblings, and controls. Arch. Gem Psychiatry (1998) 55(12):1084–1091.
   PubMedGoogle Scholar
• MCCARLEY RW, WIBLE CG, FRUMIN M et al.: MRI anatomy of schizophrenia [In Process Citation]. Biol. Psychiatry (1999) 45(9):1099–1119.
   PubMedGoogle Scholar
• WALKER E: Developmentally moderated expressionsof the neuropathology underlying schizophrenia. Schizophrenia Bulletin (1994) 20(3):453–480.
   PubMedGoogle Scholar
• •Demonstrates early pre-morbid signs in patients with schizophrenia.
   Google Scholar
• ARNOLD SE, RUSCHEINSKY DD, HAN LY: Further evidence of abnormal cytoarchitecture of the entorhinal cortex in schizophrenia using spatial point pattern analyses. Biol. Psychiatry (1997) 42 (8):639–647.
   PubMedGoogle Scholar
• CONRAD A, ABEBE T, FORSYTHE S, SCHEIBEL A: Hippocampal pyramidal cell disarray in schizo-phrenia as a bilateral phenomenon. Arch. Gen. Psychiatry (1991) 5(48):413–417.
   Google Scholar
• ZAIDEL DW, ESIRI MM, HARRISON PJ: Size, shape, andorientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia. Am. J. Psychiatry (1997) 154(6):812–818.
   PubMedGoogle Scholar
• SENITZ D: A reduction of nonpyramidal cells in sectorCA2 of schizophrenics and manic depressives [letter] [In Process Citation]. Biol. Psychiatry (1999) 45(11):1528–1530.
   PubMedGoogle Scholar
• BENES FM, KWOK EW, VINCENT SL, TODTENKOPF MS: Areduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol. Psychiatry (1998) 44(2):88–97.
   PubMedGoogle Scholar
• JAKOB H, BECKMANN H: Prenatal developmental disturbances in the limbic allocortex in schizo-phrenics. J. Neural Transmission (1986) 65:303–326.
   PubMed Web of Science ®Google Scholar
• BENES F: Neurobiological investigations in cingulate cortex of schizophrenic brain. Schizophrenia Bulletin (1993) 19:537–549.
   PubMedGoogle Scholar
• WEINBERGER D: Neurodevelopmental perspectives on schizophrenia. In: Psychopharmacology: The Fourth Generation of Progress. Bloom F, Kupfer D (Eds.), Raven Press Ltd., New York, USA (1995):1171–1183.
   Google Scholar
• CHATTERJEE A, CHAKOS M, KOREEN A et.al.: Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizo-phrenic patients. Am] Psychiatry (1995) 152:1724–1729.
   PubMed Web of Science ®Google Scholar
• BLACKWOOD D, CLAIR DS, MUIR W, DUFFY J: Auditory p300 and eye tracking dysfunction in schizophrenic pedigrees. Arch. Gen. Psychiatry (1991) 48:899–909.
   PubMed Web of Science ®Google Scholar
• FREEDMAN R, COON H, MYLES-WORSLEY M et al.: Linkage of a neurophysiological deficit in schizo-phrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA (1997) 94(2):587–592.
   PubMed Web of Science ®Google Scholar
• GOTTESMAN II: Schizophrenia Genesis: the Origins of Madness. W.H. Freeman, (1991).
   Google Scholar
• •An interesting book on the problems of schizophrenia genetics.
   Google Scholar
• KETY SS, INGRAHAM LJ: Genetic transmission and improved diagnosis of schizophrenia from pedigrees ofadoptees. j Psychiatr. Res. (1992) 26 (4) :247–255.
   Google Scholar
• FARAONE S, KREMEN W, LYONS M et al.: Diagnostic accuracy and linkage analysis: how useful are schizo-phrenia spectrum phenotypes? Am. J. Psychiatry (1995) 9(152):1286–1290.
   Google Scholar
• KENNEDY J: Schizophrenia genetics: the search for an anchor. Am. J. Psychiatry (1996) 12(152):1513–1514.
   Google Scholar
• GEJMAN PV: Chromosomes 19 and 20 report [In Process Citation]. Am. J. Med. Genet. (1999) 88(3) :271.
   PubMedGoogle Scholar
• ••References 35–47 are the most recent and comprehensivereports on schizophrenia genetics.
   Google Scholar
• DETERA-WADLEIGH SD: Chromosomes 12 and 16 workshop [In Process Citation]. Am. J. Med. Genet. (1999) 88(3):255–259.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• BARDEN N, MORISSETTE J: Chromosome 13 workshop report [In Process Citation]. Am. J. Med. Genet. (1999) 88(3)260–262.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• ALLMAYER J: Chromosomes 1,2, and 7 workshop [In Process Citation]. Am. J. Med. Genet. (1999) 88 (3):219–223.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• CRADDOCK N, LENDON C: Chromosome workshop: chromosomes 11,14, and 15 [In Process Citation]. Am. J. Med. Genet. (1999) 88(3):244–254.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• CURTIS D: Chromosome 21 workshop [In Process Citation]. Am. J. Med. Genet. (1999) 88 (3) :272–275.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• KENNEDY JL, BASILE VS, MACCIARDI FM: Chromosome 4 Workshop summary: Sixth World Congress on Psychiatric Genetics, Bonn, Germany, October 6–10, 1998 [In Process Citation]. Am. J. Med. Genet. (1999) 88(3)224–228.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• CROWE RR, VIELAND V: Report of the Chromosome 5 Workshop of the Sixth World Congress on Psychiatric Genetics [In Process Citation]. Am. J. Med. Genet. (1999) 88(3)229–232.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• NURNBERGER JI, JR., FOROUD T: Chromosome 6 workshop report [In Process Citation]. Am. J. Med. Genet. (1999) 88(3):233–238.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• WILDENAUER DB, SCHWAB SG: Chromosomes 8 and 10 workshop [In Process Citation]. Am. J. Med. Genet. (1999) 88(3):239–243.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• VAN BROECKHOVEN C, VERHEYEN G: Report of the chromosome 18 workshop [In Process Citation]. Am. J. Med. Genet. (1999) 88(3):263–270.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• SCHWAB SG, WILDENAUER DB: Chromosome 22 workshop report [In Process Citation]. Am. J. Med. Genet. (1999) 88(3):276–278.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• PATERSON AD: Sixth World Congress of Psychiatric Genetics X Chromosome Workshop [In Process Citation]. Am. J. Med. Genet. (1999) 88(3):279–286.
   PubMedGoogle Scholar
• ••See annotation to reference no. 35.
   Google Scholar
• COON H, BYERLEY W, HOLIK J, HOFF M et al.: Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees. Am. J. Med. Genet. (1994) 52(2):327–334.
   Google Scholar
• HALLMAYER J, MATER W, SCHWAB S et.al.: No evidence of linkage between the dopamine D2 receptor gene and schizophrenia. Am. J. Psychiatry (1994) 152(1):134–136.
   Google Scholar
• PERISCO AM, WANG ZW, BLACK DW et al.: Exclusion of close linkage with the dopamine transporter gene with schizophrenia spectrum disorders. Am. J. Psychiatry (1995) 152(1):134–136.
   PubMedGoogle Scholar
• NANKO S, FUKUDA R, HATTORI M et al.: Further evidence of no linkage between schizophrenia and the dopamine D3 receptor gene locus. Am. J. Med. Genet. (1994) 54(3):264–267.
   PubMedGoogle Scholar
• MATER W, SCHWAB S, HALLMAYER J et.al.: Absence of a linkage between schizophrenia and the D4 receptor gene. Psychiatry Res. (1994) 53(1):77–86.
   PubMedGoogle Scholar
• RAVINDRANATHAN A, COON H, DELISI L et al.: Linkage analysis between schizophrenia and a microsatellite polymorphism for the D5 dopamine receptor gene. Psychiatry Res. (1994) 53(1):77–86.
   PubMedGoogle Scholar
• LANDER E, KRUGLYAK L: Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nature Genet. (1995) 11:241–247.
   PubMed Web of Science ®Google Scholar
• RISCH N: Linkage strategies for genetically complex traits. II. The power of affected relative pairs. Am. J. Human Genet. (1990) 46:229–241.
   PubMed Web of Science ®Google Scholar
• RISCH N: Linkage strategies for genetically complex traits. I. Multilocus models. Am. J. Human Genet. (1990) 46:222–228.
   PubMed Web of Science ®Google Scholar
• RISCH N, MERIKANGAS K: The future of genetic studies of complex human diseases. Science (1996) 273:1516–1517.
   PubMed Web of Science ®Google Scholar
• ••A short but important paper on genetic studies.
   Google Scholar
• EASTWOOD SL, HARRISON PJ: Hippocampal and cortical growth-associated protein-43 messenger RNA in schizophrenia. Neuroscience (1998) 86(2):437–448.
   PubMedGoogle Scholar
• SOWER AC, BIRD ED, PERRONE-BIZZOZERO NI: Increased levels of GAP-43 protein in schizophrenic brain tissues demonstrated by a novel immunodetec-tion method. Mol. Chem. Neuropathol. (1995) 24 (1):1–11.
   PubMedGoogle Scholar
• THOMPSON PM, SOWER AC, PERRONE-BIZZOZERO NI:Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia. Biol. Psychiatry (1998) 43(4):239–243.
   PubMed Web of Science ®Google Scholar
• TOYOOKA K, MURATAKE T, TANAKA T et.al: 14-3-3protein eta chain gene (YWHAH) polymorphism and its genetic association with schizophrenia. Am. J. Med. Genet. (1999) 88(2):164–167.
   PubMedGoogle Scholar
• HAYAKAWA T, ISHIGURO H, TORU M, HAMAGUCHI H, ARINAMI T: Systematic search for mutations in the 14-3-3 eta chain gene on chromosome 22 in schizo-phrenics. Psychiatr. Genet. (1998) 8(1)33–36.
   PubMedGoogle Scholar
• CASTNER SA, GOLDMAN-RAKIC PS: Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsy-chopharmacology (1999) 20(1):10–28.
   PubMedGoogle Scholar
• HANTRAYE P: Modeling dopamine system dysfunction in experimental animals. Nucl. Med. Biol. (1998) 25 (8):721–728.
   PubMedGoogle Scholar
• SAMS-DODD F: A test of the predictive validity of animal models of schizophrenia based on phencycli-dine and D-amphetamine. Neuropsychopharmacology (1998) 18(4):293–304.
   PubMedGoogle Scholar
• SAMS-DODD F: Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav. Pharmacol. (1997) 8(2-3):196–215.
   PubMedGoogle Scholar
• NODA Y, YAMADA K, FURUKAWA H, NABESHIMA T: Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencycli-dine: a new model of schizophrenia. Br. J. Pharmacol. (1995) 116(5):2531–2537.
   PubMedGoogle Scholar
• REIJMERS LG, VANDERHEYDEN PM, PEETERS BW: Changes in prepulse inhibition after local administra-tion of NMDA receptor ligands in the core region of the rat nucleus accumbens. Eur. J. Pharmacol (1995) 272 (2-3):131–138.
   PubMedGoogle Scholar
• JOHNSTON MV, BARKS J, GREENAMYRE T, SILVERSTEINF: Use of toxins to disrupt neurotransmitter circuitry in the developing brain. Prog. Brain Res. (1988) 73:425–446.
   PubMedGoogle Scholar
• LILLRANK SM, LIPSKA BK, WEINBERGER DR: Neurodevel-opmental animal models of schizophrenia. Clin. Neurosci. (1995) 3(2):98–104.
   PubMedGoogle Scholar
• LIPSKA BK, SWERDLOW NR, GEYER MA et al.: Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharma-cology (1995) 122:35–43.
   PubMed Web of Science ®Google Scholar
• STEVENS KE, NAGAMOTO H, JOHNSON RG, ADAMS CE, ROSE GM: Kainic acid lesions in adult rats as a model of schizophrenia: changes in auditory information processing. Neuroscience (1998) 82(3)701–708.
   PubMedGoogle Scholar
• BARDGETT ME, JACKSON JL, TAYLOR GT, CSERNANSKY JG: Kainic acid decreases hippocampal neuronal number and increases dopamine receptor binding in the nucleus accumbens: an animal model of schizo-phrenia. Behav. Brain Res. (1995) 70(2):153–164.
   PubMedGoogle Scholar
• SHALEV U, FELDON J, WEINER I: Gender- and age-dependent differences in latent inhibition following pre-weaning non-handling: implications for a neurodevelopmental animal model of schizo-phrenia. Int. J. Dev. Neurosci. (1998) 16(3-4):279–288.
   PubMedGoogle Scholar
• LILLRANK SM, LIPSKA BK, WEINBERGER DR: Neurodevel-opmental animal models of schizophrenia. Clin. Neurosci. (1995) 3:98–104.
   PubMedGoogle Scholar
• JOSSELYN SA, VACCARINO FJ: Preclinical behavioral approaches to the identification and study of antipsy-chotic drug action and schizophrenia. In: In Vivo Neuromethods. Boulton AA, Baker GR, Bateson AN (Eds.), Humana Press Inc, Totowa, NJ, USA (1998):177–225.
   Google Scholar
• SWERDLOW NR, GEYER MA: Using an animal model of deficient sensorimotor gating to study the pathophysi-ology and new treatments of schizophrenia. Schizophr. Bull. (1998) 24(2):285–301.
   PubMedGoogle Scholar
• ELLENBROEK BA, GEYER MA, COOLS AR: The behavior of APO-SUS rats in animal models with construct validity for schizophrenia. J. Neurosci. (1995) 15(11):7604–7611.
   PubMedGoogle Scholar
• BRENNER HD, DENCKER SJ, GOLDSTEIN MJ et al.: Defining treatment refractoriness in schizophrenia. Schizophr. Bull. (1990) 16(4):551–561.
   PubMed Web of Science ®Google Scholar
• TAMMINGA CA: The promise of new drugs for schizo-phrenia treatment [see comments]. Can. J. Psychiatry (1997) 42(3):265–273.
   PubMedGoogle Scholar
• •A good review of preclinical drug characteristics predicting clinical benefits of new and old antipsychotics.
   Google Scholar
• GILBERT PL, HARRIS MJ, MCADAMS LA, JESTE DV: Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch. Gen. Psychiatry (1995) 52(3):173–188.
   PubMed Web of Science ®Google Scholar
• JIBSON M, TANDON R: The negative symptoms of schizophrenia. Direct. Psychiatry (1995) 15:1–7.
   Google Scholar
• BILDER RM: Neurocognitive impairment in schizo-phrenia and how it affects treatment options [see comments]. Can. J. Psychiatry (1997) 42(3):255–264.
   PubMedGoogle Scholar
• CHATTERJEE A, CHAKOS M, KOREEN A et al.: Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizo-phrenic patients. Am. J. Psychiatry (1 9 9 5) 152 (12):1724–1729.
   PubMedGoogle Scholar
• ••A prospective study correlating early EPS and the develop-ment of parkinsonian symptoms with antipsychotic use.
   Google Scholar
• HANSEN TE, CASEY DE, HOFFMAN WF: Neuroleptic intolerance. Schizophr. Bull. (1997) 23(4):567–82.
   PubMedGoogle Scholar
• CARLSSON A, LINDQUIST M: Effect of chlorpromazineand haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharma-cologica Toxicologica (1963) 20:140–144.
   PubMedGoogle Scholar
• LIEBERMAN JA, KANE JM, ALVIR J: Provocative tests withpsychostimulant drugs in schizophrenia. Psychophar-macology (Berl) (1987) 91(4):415–433.
   PubMed Web of Science ®Google Scholar
• RANDRUP A, MUNKVAD I: Special antagonism of amphetamine-induced abnormal behaviour. Inhibi-tion of stereotyped activity with increase of some normal activities. Psychopharmacologia (19 6 5) 7 (6) :416–422.
   PubMedGoogle Scholar
• SNYDER SH: Amphetamine psychosis: a 'model' schizo-phrenia mediated by catecholamines. Am. J. Psychiatry (1973) 130(1):61–67.
   PubMed Web of Science ®Google Scholar
• SEEMAN P, LEE T: Antipsychotic drugs: direct correla-tion between clinical potency and presynaptic action ondopamine neurons. Science (1 9 7 5)188(4194):1217–1219.
   Google Scholar
• ••This paper and reference no. 91 are landmark articlesestablishing the role of DA receptors in antipsychotic action.
   Google Scholar
• SEEMAN P, LEE T, CHAU-WONG M, WONG K: Antipsy-chotic drug doses and neuroleptic/dopamine receptors. Nature (1976) 261(5562)717–719.
   PubMedGoogle Scholar
• ••See annotation to reference no. 90.
   Google Scholar
• SEEMAN P: Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology (1 9 9 2) 7(4):261–284.
   PubMedGoogle Scholar
• •A correlative study showing that at therapeutic doses clozapine is more likely to occupy D4, and not D2, receptors.
   Google Scholar
• CREESE I, BURT DR, SNYDER SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science (1976) 192(4238)481–483.
   PubMedGoogle Scholar
• SEEMAN P: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse (19 8 7) 1(2):133–152.
   PubMedGoogle Scholar
• ••A detailed review of the DA hypothesis of schizophrenia.
   Google Scholar
• FARDE L, NORDSTROM AL, WIESEL FA et al.: Positronemission tomographic analysis of central Di and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry (1992) 49(7)538–544.
   PubMedGoogle Scholar
• MELTZER HY, LEE MA, RANJAN R: Recent advances in thepharmacotherapy of schizophrenia. Acta Psychiatr. Scand. Suppl (1994) 384:95–101.
   PubMedGoogle Scholar
• •A comparative study assessing the clinical benefits of clozapine and other novel antipsychotics.
   Google Scholar
• LEE MA, THOMPSON PA, MELTZER HY: Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry (1994) 55 (Suppl. B):82–87.
   PubMedGoogle Scholar
• BUCHANAN RW, HOLSTEIN C, BREIER A: The compara-tive efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry (1994) 36(11):717–725.
   PubMed Web of Science ®Google Scholar
• LINDENMAYER JP, GROCHOWSKI S, MABUGAT L: Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizo-phrenics. J. Gun. Psychopharmacol. (1994) 14(3)201–204.
   PubMedGoogle Scholar
• BREIER A, BUCHANAN RW, KIRKPATRICK B et al.: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry (1994) 151(1):20–26.
   PubMed Web of Science ®Google Scholar
• •A study evaluating clozapine's efficacy in positive and negative symptoms in schizophrenic out-patients.
   Google Scholar
• KANE J, HONIGFELD G, SINGER J, MELTZER H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry (1988) 45(9):789–796.
   PubMed Web of Science ®Google Scholar
• ••A crucial study revealing clozapine's efficacy in treatment-resistant schizophrenics.
   Google Scholar
• LIEBERMAN JA, MAILMAN RB, DUNCAN G et al.: Seroto-nergic basis of antipsychotic drug effects in schizo-phrenia. Biol. Psychiatry (1998) 44(11):1099–1117.
   PubMedGoogle Scholar
• KALKMAN HO, NEUMANN V, TRICKLEBANK MD: Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Naunyn. Schmiedebergs Arch. Pharmacol (1997) 355(3):361–364.
   PubMedGoogle Scholar
• JANSSEN PA, NIEMEGEERS CJ, AWOUTERS F et al.: Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-52 and dopamine-D2 antagonistic properties. J. Pharmacol. Exp. Then. (1988) 244(2)685–693.
   PubMedGoogle Scholar
• MARDER SR, MEIBACH RC: Risperidone in the treatment of schizophrenia. Am. J. Psychiatry (1 9 9 4) 15 1 (6):825–835.
   Google Scholar
• PEUSKENS J: Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group [see comments]. Br. J. Psychiatry (1995) 166(6):712–726.
   PubMed Web of Science ®Google Scholar
• BORISON RL: Recent advances in the pharmacotherapy of schizophrenia. Harv. Rev. Psychiatry (19 9 7) 4 (5):255–271.
   PubMedGoogle Scholar
• BYMASTER FP, CALLIGARO DO, FALCONE JF et al.: Radioreceptor binding profile of the atypical antipsy-chotic olanzapine. Neuropsychopharmacology (1996) 14(2)87–96.
   PubMedGoogle Scholar
• MOORE NA, TYE NC, AXTON MS, RISIUS FC: The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J. Pharmacol. Exp. Ther. (1992) 262(2):545–551.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON GD, SANGER TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry (1997) 154(4):466–474.
   PubMed Web of Science ®Google Scholar
• BEASLEY CM, JR., SANGER T, SATTERLEE W et al.: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Ber) (1996) 124(1-2):159–167.
   PubMed Web of Science ®Google Scholar
• BLAKE TJ, TILLERY CE, REYNOLDS GP: Antipsychotic drug affinities at alpha2-adrenoceptor subtypes in post-mortem human brain. J. Psychopharmacol. (1998) 12(2)151–154.
   PubMedGoogle Scholar
• HYTTEL J, NIELSEN JB, NOWAK G: The acute effect of sertindole on brain 5-111'2, Dy and alpha 1 receptors (ex vivo radioreceptor binding studies). J. Neural Transm. Gen. Sect. (1992) 89(1-2):61–69.
   PubMed Web of Science ®Google Scholar
• SKARSFELDT T, PERREGAARD J: Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. Eur. J. Pharmacol (1990) 182 (3) :613–614.
   PubMedGoogle Scholar
• NORDSTROM AL, FARDE L, WIESEL FA et al.: Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry (1993) 33 (4):227–235.
   PubMedGoogle Scholar
• KAPUR S, ZIPURSKY RB, REMINGTON G et al.: 5-11T2 and Dy receptor occupancy of olanzapine in schizo-phrenia: a PET investigation. Am. J. Psychiatry (1998) 155 (7):921–928.
   PubMed Web of Science ®Google Scholar
• KAPUR S, ZIPURSKY RB, REMINGTON G: Clinical and theoretical implications of 5-11T2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry (1999) 156(2)286–293.
   PubMedGoogle Scholar
• ••A key study evaluating the importance of 5-HT2 and D2receptor occupancy with effective novel antipsychotics.
   Google Scholar
• SEEMAN P, TALLERICO T: Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Ma Psychiatry (1998) 3 (2) :123–134.
   Google Scholar
• •An extensive review of the correlation of antipsychotics with low EPS and TD potential and their loose affinity for D2.
   Google Scholar
• SEEMAN P, CORBETT R, NAM D, VAN TOL HH: Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism. Jpn. J. Pharmacol. (1996) 71(3):187–204.
   PubMedGoogle Scholar
• SEEMAN P, CORBETT R, VAN TOL HH: Atypical neuroleptics have low affinity for dopamine Dy receptors or are selective for D4 receptors. Neuropsy-chopharmacology (1997) 16(2):93–110.
   PubMedGoogle Scholar
• VAN TOL HH, BUNZOW JR, GUAN HC et al.: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature (1991) 350(6319)610–614.
   PubMedGoogle Scholar
• WILSON JM, SANYAL S, VAN TOL HH: Dopamine D2 and D4 receptor ligands: relation to antipsychotic action. Eur. j Pharmacol. (1998) 351 (3):273–286.
   PubMed Web of Science ®Google Scholar
• KRAMER MS, LAST B, GETSON A, REINES SA: The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group [published erratum appears in Arch. Gen. Psychiatry (1997) 54(12):1080]. Arch. Gen. Psychiatry (1997) 54 (6):567–572.
   PubMedGoogle Scholar
• TRUFFINET P, TAMMINGA CA, FABRE LF et al.: Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am. J. Psychiatry (1999) 156(3):419–425.
   PubMedGoogle Scholar
• FRIEDMAN JI, TEMPORINI H, DAVIS KL: Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol. Psychiatry (1999) 45 (1) :1–16.
   PubMedGoogle Scholar
• MRZLJAK L, BERGSON C, PAPPY M et al. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature (1996) 381(6579)245–248.
   PubMedGoogle Scholar
• JENTSCH JD, TAYLOR JR, REDMOND DE, JR et al. Dopamine D4 receptor antagonist reversal of sub chronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharma-cology (Berl) (1999) 142 (1) 78–84
   PubMedGoogle Scholar
• MURPHY BL, ARNSTEN AF, GOLDMAN-RAKIC PS, ROTH RH: Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc. Natl. Acad. Sci. USA (1996) 93 (3):1325–1329.
   PubMedGoogle Scholar
• MURPHY BL, ROTH RH, ARNSTEN AF: Clozapine reverses the spatial working memory deficits induced by FG7142 in monkeys. Neuropsychopharmacology (1997) 16(6):433–437.
   PubMedGoogle Scholar
• JENTSCH JD, REDMOND DE, JR., ELSWORTH JD et al.: Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administra-tion of phencyclidine. Science (1997) 277 (5328) 953–955.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ JC, GRIFFON N, DIAZ J et al.: The D3 receptor and its relevance in psychiatry. Int. Clin. Psychophar-macol. (1995) 10 (Suppl. 3):15–20.
   PubMedGoogle Scholar
• SAUTEL F, GRIFFON N, SOKOLOFF P et al.: Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. (1995) 275(3):1239–1246.
   PubMed Web of Science ®Google Scholar
• LAHTI AC, WEILER M, CARLSSON A, TAMMINGA CA: Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-U11232 in schizophrenia. J. Neural Transm. (1998) 105(6-7):719–734.
   PubMedGoogle Scholar
• SMITH AG, NEILL JC, COSTALL B: The dopamine D3/D2 receptor agonist 7-011-DPAT induces cognitive impair-ment in the marmoset [In Process Citation]. Pharmacol. Biochem. Behav. (1999) 63(2):201–211.
   PubMedGoogle Scholar
• MILLAN MJ, GRESSIER H, BROCCO M: The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur. J. Pharmacol. (1997) 3 2 1 (3):R7–9.
   Google Scholar
• WITKIN J, GASIOR M, ACRI J et al.: Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907. Eur. J. Pharmacol. (1998) 347 (2-3):R1–3.
   PubMedGoogle Scholar
• DAVIS KL, KAHN RS, KO G, DAVIDSON M: Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry (1991) 148(1 1) :1474–1486.
   PubMed Web of Science ®Google Scholar
• ••A key study reviewing that a simultaneous hypodopamin-ergic function in the PFC and a hyperdopamine function in the subcortical regions may be responsible for producing the negative and positive symptoms of schizophrenia respectively.
   Google Scholar
• SAWAGUCHI T, GOLDMAN-RAKIC PS: Di dopamine receptors in prefrontal cortex: involvement in working memory. Science (1991) 251 (4996):947–950.
   PubMedGoogle Scholar
• •A key study showing the involvement of Di receptors in working memory.
   Google Scholar
• SAWAGUCHI T, GOLDMAN-RAKIC PS: The role of Di-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J. Neurophysiol. (19 9 4) 71(2):515–528.
   PubMedGoogle Scholar
• ARNSTEN AF, CAI JX, MURPHY BL, GOLDMAN-RAKIC PS: Dopamine Di receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Ber) (1994) 116(2):143–151.
   PubMed Web of Science ®Google Scholar
• WILLIAMS GV, GOLDMAN-RAKIC PS: Modulation of memory fields by dopamine Di receptors in prefrontal cortex. Nature (1995) 376(6541):572–575.
   PubMed Web of Science ®Google Scholar
• OKUBO Y, SUHARA T, SUZUKI K et al.: Decreased prefrontal dopamine Di receptors in schizophrenia revealed by PET. Nature (1997) 385 (6617):634–636.
   PubMed Web of Science ®Google Scholar
• KNABLE MB, HYDE TM, MURRAY AM, HERMAN MM, KLEINMAN JE: A postmortem study of frontal cortical dopamine Di receptors in schizophrenics, psychiatric controls, and normal controls. Biol. Psychiatry (1996) 40(12):1191–1199.
   PubMedGoogle Scholar
• BRUNELLO N, MASOTTO C, STEARDO L, MARKSTEIN R, RACAGNI G: New insights into the biology of schizo-phrenia through the mechanism of action of clozapine. Neuropsychopharmacology (1 9 9 5) 13 (3):177–213.
   PubMedGoogle Scholar
• •A good review of the potential mechanism of clozapine's action.
   Google Scholar
• MELTZER HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Ben) (1989) 99(Suppl.):518–27.
   PubMedGoogle Scholar
• •An alternative hypothesis suggesting clozapine's atypicality rests in its ability to occupy both DA and serotonin receptors.
   Google Scholar
• GELDERS YG: Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br. J. Psychiatry Stipp]. (1989) (5):33–36.
   Google Scholar
• DUINKERKE SJ, BOTTER PA, JANSEN AA et.al: Ritanserin, a selective 5-11T2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br. J. Psychiatry (1993) 163:451–455.
   PubMed Web of Science ®Google Scholar
• GERLACH J: New antipsychotics: classification, efficacy, and adverse effects. Schizophr. Bull. (1991) 17(2)289–309.
   PubMedGoogle Scholar
• WALDMEIER PC, DELINI-STULA AA: Serotonin-dopamine interactions in the nigrostriatal system. Eur. J. Pharmacol. (1979) 55(4):363–373.
   PubMedGoogle Scholar
• BLEICH A, BROWN SL, KAHN R, VAN PRAAG HM: The role of serotonin in schizophrenia. Schizophr. Bull. (1988) 14 (2):297–315.
   PubMedGoogle Scholar
• •An extensive review of the role of serotonin in schizophrenia.
   Google Scholar
• MILLER RJ, HILEY CR: Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature (1974) 248(449)596–597.
   PubMedGoogle Scholar
• SNYDER SH, GREENBERG D, YAMUMURA HI: Antischizo-phrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects. J. Psychiatr. Res. (1974) 11:91–95.
   PubMedGoogle Scholar
• TUNE LE, STRAUSS ME, LEW MF, BREITLINGER E, COYLE JT: Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am. J. Psychiatry (1982) 139(11):1460–1462.
   PubMed Web of Science ®Google Scholar
• STRAUSS ME, REYNOLDS KS, JAYARAM G, TUNE LE: Effects of anticholinergic medication on memory in schizophrenia. Schizophr. Res. (1990) 3 (2):127–129.
   PubMed Web of Science ®Google Scholar
• DEQUARDO JR: Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J. Clin. Psychiatry (1998) 59(Suppl. 19):9–17.
   PubMedGoogle Scholar
• MCGLASHON TH, JOHANNESSES JO: Early detection and intervention with schizophrenia: rationale. Schizophr. Bull. (1996) 22(2):201–222.
   PubMedGoogle Scholar
• MCGLASHAN TH: Early detection and intervention of schizophrenia: rationale and research. Br. J Psychiatry Suppl (1998) 172(33):3–6.
   PubMedGoogle Scholar
• JACKSON HJ, MCGORRY PD, DUDGEON P: Prodromal symptoms of schizophrenia in first-episode psychosis: prevalence and specificity [published erratum appears in Compr. Psychiatry (1996) 37(1):75]. Compr. Psychiatry (1995) 36(0241–250.
   PubMed Web of Science ®Google Scholar
• MCGORRY PD, MCFARLANE C, PATTON GC et al.: The prevalence of prodromal features of schizophrenia in adolescence: a preliminary survey. Acta Psychiatr. Scand. (1995) 92(4):241–249.
   PubMedGoogle Scholar
• WADDINGTON JL, SCULLY PJ, O'CALLAGHAN E: The new antipsychotics and their potential for early interven-tion in schizophrenia. Schiz. Res. (1997) 28(2-3) :207–222.
   PubMedGoogle Scholar
• YUNG AR, MCGORRY PD: Is pre-psychotic intervention realistic in schizophrenia and related disorders? Aust. NZ J. Psychiatry (1997) 31(6):799–805.
   PubMed Web of Science ®Google Scholar
• VERMA IM, SOMIA N: Gene therapy - promises, problems and prospects [news]. Nature (1997) 389(6648)239–242.
   PubMedGoogle Scholar
• •A good review of gene therapy.
   Google Scholar
• LESCH K: Gene transfer to the brain: emerging therapeutic strategy in psychiatry? Biol. Psychiatry (1999) 45(3):247–253.
   Google Scholar
• ••A review outlining the potential of gene transfer inpsychiatry.
   Google Scholar
• KARPATI G, LOCHMULLER H, NALBANTOGLU J, DURHAM H: The principles of gene therapy for the nervous system. Trends NeuroscL (1996) 19(2)49–54.
   PubMedGoogle Scholar
• •An extensive review of gene therapy in the CNS.
   Google Scholar
• GARDNER W: Can human genetic enhancement be prohibited? J. Med. Philos. (1995) 20 (1):65–84.
   PubMedGoogle Scholar
• KNAPP M, WONG AH, SCHOOTS O, GUAN HC, VAN TOL HH: Promoter-independent regulation of cell-specific dopamine receptor expression. FEBS Lett. (1998) 434 (1-2):108–114.
   PubMedGoogle Scholar
• WEISS B, DAVIDKOVA G, ZHOU LW, ZHANG SP, MORABITO M: Expression of a D2 dopamine receptor antisense RNA in brain inhibits D2-mediated behaviors. Neurochem. Int. (1997) 31(4):571–580.
   PubMedGoogle Scholar
• TEPPER JM, SUN BC, MARTIN LP, CREESE I: Functional roles of dopamine D2 and D3 autoreceptors on nigros-triatal neurons analyzed by antisense knockdown in vivo. J. Neurosci. (1997) 17(7):2519–2530.
   PubMedGoogle Scholar
• WEIDEN P, AQUILA R, STANDARD J: Atypical antipsy-chotic drugs and long-term outcome in schizophrenia. Clin. Psychiatry (1996) 57 (Suppl. 11):53–60.
   PubMedGoogle Scholar